82 related articles for article (PubMed ID: 18554255)
1. Crown ether-peptide construct selectively kills cancer cells.
Rotello VM
Chem Biol Drug Des; 2008 Jul; 72(1):1-2. PubMed ID: 18554255
[No Abstract] [Full Text] [Related]
2. Nanoscale tools to selectively destroy cancer cells.
Boudreault PL; Arseneault M; Otis F; Voyer N
Chem Commun (Camb); 2008 May; (18):2118-20. PubMed ID: 18438487
[TBL] [Abstract][Full Text] [Related]
3. Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
Marjanović M; Kralj M; Supek F; Frkanec L; Piantanida I; Smuc T; Tusek-Bozić L
J Med Chem; 2007 Mar; 50(5):1007-18. PubMed ID: 17300184
[TBL] [Abstract][Full Text] [Related]
4. Could LogP be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns.
Supek F; Ramljak TŠ; Marjanović M; Buljubašić M; Kragol G; Ilić N; Smuc T; Zahradka D; Mlinarić-Majerski K; Kralj M
Eur J Med Chem; 2011 Aug; 46(8):3444-54. PubMed ID: 21628081
[TBL] [Abstract][Full Text] [Related]
5. Crown ether ring-fused nucleosides: synthesis and conformational properties.
Coppola C; D'Onofrio J; Di Fabio G; De Napoli L; Montesarchio D
Nucleic Acids Symp Ser (Oxf); 2008; (52):667-8. PubMed ID: 18776556
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity.
Liang JF; Yang VC
Bioorg Med Chem Lett; 2005 Nov; 15(22):5071-5. PubMed ID: 16168650
[TBL] [Abstract][Full Text] [Related]
7. TMTP1, a novel tumor-homing peptide specifically targeting metastasis.
Yang W; Luo D; Wang S; Wang R; Chen R; Liu Y; Zhu T; Ma X; Liu R; Xu G; Meng L; Lu Y; Zhou J; Ma D
Clin Cancer Res; 2008 Sep; 14(17):5494-502. PubMed ID: 18765541
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of aza-crown ether-squaramide conjugates as anion/cation symporters.
Yu XH; Cai XJ; Hong XQ; Tam KY; Zhang K; Chen WH
Future Med Chem; 2019 May; 11(10):1091-1106. PubMed ID: 31280669
[No Abstract] [Full Text] [Related]
9. Luminescent crown ether amino acids: selective binding to N-terminal lysine in peptides.
Mandl CP; König B
J Org Chem; 2005 Jan; 70(2):670-4. PubMed ID: 15651816
[TBL] [Abstract][Full Text] [Related]
10. The NK-lysin derived peptide NK-2 preferentially kills cancer cells with increased surface levels of negatively charged phosphatidylserine.
Schröder-Borm H; Bakalova R; Andrä J
FEBS Lett; 2005 Nov; 579(27):6128-34. PubMed ID: 16269280
[TBL] [Abstract][Full Text] [Related]
11. The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.
Huq A; Singh B; Meeker T; Mascarenhas D
Anticancer Drugs; 2009 Jan; 20(1):21-31. PubMed ID: 19342998
[TBL] [Abstract][Full Text] [Related]
12. A [3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines.
Plazuk D; Vessières A; Hillard EA; Buriez O; Labbé E; Pigeon P; Plamont MA; Amatore C; Zakrzewski J; Jaouen G
J Med Chem; 2009 Aug; 52(15):4964-7. PubMed ID: 19526991
[TBL] [Abstract][Full Text] [Related]
13. Antitumoral and other biomedical activities of synthetic ether lysophospholipids.
Munder PG; Westphal O
Chem Immunol; 1990; 49():206-35. PubMed ID: 2190582
[No Abstract] [Full Text] [Related]
14. Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
Giardinà D; Martarelli D; Sagratini G; Angeli P; Ballinari D; Gulini U; Melchiorre C; Poggesi E; Pompei P
J Med Chem; 2009 Aug; 52(15):4951-4. PubMed ID: 19719240
[TBL] [Abstract][Full Text] [Related]
15. Biomedical potentials of crown ethers: prospective antitumor agents.
Kralj M; Tusek-Bozić L; Frkanec L
ChemMedChem; 2008 Oct; 3(10):1478-92. PubMed ID: 18683175
[TBL] [Abstract][Full Text] [Related]
16. Construction of a crown ether-like supramolecular library by conjugation of genetically-encoded peptide linkers displayed on bacteriophage T7.
Fukunaga K; Hatanaka T; Ito Y; Minami M; Taki M
Chem Commun (Camb); 2014 Apr; 50(30):3921-3. PubMed ID: 24619095
[TBL] [Abstract][Full Text] [Related]
17. Discovery and potency optimization of 2-amino-5-arylmethyl-1,3-thiazole derivatives as potential therapeutic agents for prostate cancer.
Krasavin M; Karapetian R; Konstantinov I; Gezentsvey Y; Bukhryakov K; Godovykh E; Soldatkina O; Lavrovsky Y; Sosnov AV; Gakh AA
Arch Pharm (Weinheim); 2009 Jul; 342(7):420-7. PubMed ID: 19544302
[TBL] [Abstract][Full Text] [Related]
18. Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells.
Wang KR; Yan JX; Zhang BZ; Song JJ; Jia PF; Wang R
Cancer Lett; 2009 Jun; 278(1):65-72. PubMed ID: 19233550
[TBL] [Abstract][Full Text] [Related]
19. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides.
Makovitzki A; Fink A; Shai Y
Cancer Res; 2009 Apr; 69(8):3458-63. PubMed ID: 19351852
[TBL] [Abstract][Full Text] [Related]
20. On the selectivity and efficacy of defense peptides with respect to cancer cells.
Harris F; Dennison SR; Singh J; Phoenix DA
Med Res Rev; 2013 Jan; 33(1):190-234. PubMed ID: 21922503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
